• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Biomerica Inc.

    12/20/24 5:01:09 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $BMRA alert in real time by email
    S-8 1 forms-8.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    Under

    THE SECURITIES ACT OF 1933

     

    BIOMERICA, INC.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   95-2645573
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)
         
    17571 Von Karman Avenue, Irvine, California   92614
    (Address of principal executive offices)   (Zip Code)

     

    BIOMERICA, INC.
    2024 STOCK INCENTIVE PLAN

    (Full title of the plan)

     

    Zackary Irani

    Chief Executive Officer

    Biomerica, Inc.

    17571 Von Karman Avenue

    Irvine, California 92614

    (Name and address of agent for service)

     

    (949) 645-2111

    (Telephone number, including area code, of agent for service)

     

    Copy to:

    Christopher D. Ivey, Esq.

    Stradling Yocca Carlson & Rauth LLP

    660 Newport Center Drive, Suite 1600

    Newport Beach, California 92660

    (949) 725-4000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
           
    Non-accelerated filer ☒ Smaller reporting company ☒
           
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Biomerica, Inc., a Delaware corporation (the “Registrant” or “Company”), to register 1,600,000  shares of the Registrant’s common stock, par value $0.08 per share (the “Common Stock”), to be issued under the 2024 Stock Incentive Plan (the “Plan”) that was duly adopted and approved by the Registrant’s stockholders on December 13, 2024.

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the Plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have been filed by the Registrant with the Securities and Exchange Commission (the “Commission”) are hereby incorporated by reference herein, and shall be deemed to be a part of, this Registration Statement:

     

      ● The Registrant’s Annual Report on Form 10-K for the fiscal year ended May 31, 2024, filed with the Commission on August 28, 2024 (the “Annual Report”);
         
      ● The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2024, filed with the Commission on October 15, 2024;
         
      ● The Registrant’s Current Reports on Form 8-K filed with the Commission on June 28, 2024, November 6, 2024, and December 17, 2024 (only those portions deemed filed and not furnished); and
         
      ● The description of the Registrant’s Common Stock contained in Exhibit 4.2 to the Annual Report, and any other amendment or report filed for the purpose of updating such description.

     

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities and Exchange Act of 1934, as amended, after the date of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered have been sold, or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part of it from the respective dates of filing such documents; except as to any portion of any future annual, quarterly or current report or other document, or any portion thereof, that is deemed furnished and not deemed filed under such provisions. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document, which also is or is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not required to be filed with this Registration Statement.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not Applicable.

     

     

     

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 102 of the General Corporation Law of the State of Delaware (the “DGCL”) permits a corporation to eliminate the personal liability of directors or officers of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director or officer breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, obtained an improper personal benefit, or where the director authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law.

     

    Subsection (a) of Section 145 of the DGCL empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful.

     

    Subsection (b) of Section 145 of the DGCL empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities set forth above, against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

     

    Section 145 of the DGCL further provides that, to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a) and (b) of Section 145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section 145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section 145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person’s heirs, executors and administrators. Section 145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section 145.

     

    The Company’s First Amended and Restated Certificate of Incorporation (the “Charter”) provides that, to the fullest extent permitted by the DGCL, no director of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director. The effect of this provision as permitted by Section 102 of the DGCL, is to eliminate the Company’s rights and those of its stockholders (through stockholders’ derivative suits on behalf of the Company) to recover damages against a director for breach of the fiduciary duties as a director (including breaches resulting from negligent or grossly negligent behavior), except under certain situations defined by statute.

     

     

     

     

    In addition, as permitted by Section 145 of the DGCL, the Company’s Amended and Restated Bylaws (the “Bylaws”) provide that the Company is required to indemnify its directors and officers and persons serving in these capacities in other business enterprises (including, for example, the Company’s subsidiaries) at the Company’s request, to the fullest extent permitted by the DGCL, including in those circumstances in which indemnification would otherwise be discretionary. The Company’s Bylaws also provide that the Company may indemnify its employees and agents in circumstances where indemnification is not required by law. The rights conferred in the Bylaws are not exclusive, and the Company is authorized to enter into indemnification agreements with its directors, executive officers and employees. The Company may not retroactively amend its Bylaws in a way that reduces the protections of its directors, officers and employees who benefit from such provisions.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, or otherwise, the Company have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.

     

    Item 7. Exemption from Registration Claimed.

     

    Not Applicable.

     

    Item 8. Exhibits.

     

    A list of exhibits filed with this Registration Statement is set forth in the Exhibit Index hereto and is incorporated herein by reference.

     

     

     

     

    Item 9. Undertakings.

     

    (a) The Registrant hereby undertakes:

     

    1. To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    i. To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    ii. To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 change in the maximum aggregate offering price set forth in Exhibit 107 (Filing Fee Table) to the Registration Statement; and

     

    iii. To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    Provided however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    2. That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on December 20, 2024.

     

      BIOMERICA, INC.
       
      By: /s/ Zackary Irani
        Zackary Irani
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Zackary Irani and Gary Lu and each them, individually, as his or her attorneys-in-fact, with full power and authority, including full power of substitution, for the undersigned to sign, in any and all capacities, any amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and to do any and all acts and things for and in name of the undersigned which such attorneys-in-fact, or any of them, individually, may deem necessary or advisable to enable Biomerica, Inc. to comply with the Securities Act of 1933, as amended, and any rules, regulations, and requirements of the Securities and Exchange Commission, in connection with this Registration Statement, and does hereby ratify and confirm all that any of said attorneys-in-fact, or any of their substitutes, may do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the respective capacities and on the dates indicated below.

     

    Name   Title   Date
             
    /s/ Zackary S. Irani   Chief Executive Officer and Director   December 20, 2024
    Zackary S. Irani   (Principal Executive Officer)    
             
    /s/ Gary Lu, CPA   Chief Financial Officer   December 20, 2024
    Gary Lu   (Principal Financial and Accounting Officer)    
             
    /s/ Allen Barbieri   Director, Vice Chairman and Secretary   December 20, 2024
    Allen Barbieri        
             
    /s/ David Moatazedi   Director   December 20, 2024
    David Moatazedi        
             
    /s/ Jane Emerson, M.D., Ph. D.   Director   December 20, 2024
    Jane Emerson, M.D., Ph. D        
             
    /s/ Catherine Coste, CPA   Director   December 20, 2024
    Catherine Coste, CPA        

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description of Exhibit
    4.1   Biomerica, Inc. 2024 Stock Incentive Plan (incorporated herein by reference to Exhibit A to the Registrant’s Definitive Proxy Statement filed with the Commission on September 30, 2024).
         
    5.1   Opinion of Stradling Yocca Carlson & Rauth LLP±
         
    23.1   Consent of Haskell and White LLP ±
         
    23.2   Consent of Stradling Yocca Carlson & Rauth LLP (included in Exhibit 5.1)±
         
    24.1   Power of Attorney (included on the signature page of this registration statement)±
         
    107   Filing Fee Table±

     

    ± Filed herewith.

     

     

     

    Get the next $BMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biomerica Inc.

      SC 13G/A - BIOMERICA INC (0000073290) (Subject)

      11/14/24 4:19:51 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Biomerica Inc. (Amendment)

      SC 13G/A - BIOMERICA INC (0000073290) (Subject)

      2/14/24 9:00:06 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Biomerica Inc.

      SC 13G - BIOMERICA INC (0000073290) (Subject)

      2/9/24 3:06:57 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Emerson Jane was granted 85,000 shares, increasing direct ownership by 120% to 156,000 units (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:09 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Coste Catherine was granted 85,000 shares, increasing direct ownership by 194% to 128,790 units (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:05 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Moatazedi David was granted 85,000 shares (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:07 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board

      IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, "LabCorp" (NYSE:LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product. Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world's largest diagnostics clinical laboratories, boasting $7B in annual revenues, ov

      2/21/24 8:19:00 AM ET
      $BMRA
      $LH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Medical Specialities
    • Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica

      Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built and ultimately managed the sale of the company for $1.53 billion IRVINE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to serve as the Chairman of the Board of Directors of Biomerica. Mr. Zack Irani will continue to serve as CEO. Mr. Kenny joined the Biomerica Board of Director

      1/23/24 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Diagnostics Industry Leader Jack Kenny Joins Biomerica's Board of Directors

      Kenny has proven track record of driving growth at companies within the healthcare space and holds significant management and public company board experience, most recently as CEO of Meridian BioscienceAs CEO Kenny managed the sale of Meridian Biosciences in an all-cash transaction valued at approximately $1.53 billion NEWPORT BEACH, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to its Board of Directors. Meridian Biosciences (formerly traded on Nasdaq under VIVO) is a leadin

      8/28/23 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Financials

    Live finance-specific insights

    See more

    $BMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022

      InFoods® IBS Data Receives American College of Gastroenterology Presidential Award (ACG) Following Presentation at Annual Scientific Meeting  Trial Data Shows InFoods® IBS Treatment Diet Significantly Improved Several IBS Symptoms Including Abdominal Pain Intensity (API): In Some Cases Better Than Certain Currently Marketed Drugs  Launch of InFoods® IBS Lab Developed Test Expected in Fiscal 3Q  Amazon Now Fulfills Sales of Aware® Breast Self Exam and EZ Detect™ Colon Disease Tests IRVINE, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- IRVINE, CABiomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products, today reported its second quarter fiscal 2023 fina

      1/13/23 6:39:00 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System

      Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period First-of-Its-Kind inFoods® IBS Feedback Platform: New real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomesPrecision Medicine: inFoods® IBS identifies specific individual food triggers that can cause IBS symptoms (bloating, pain, diarrhea, and constipation) offering a personalized, non-drug solution IRVINE, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today anno

      5/22/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement

      - Application represents milestone toward broadening patient access to inFoods IBS - inFoods® IBS pinpoints patient-specific foods that can trigger IBS symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif. , May 07, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company dedicated to the development of advanced diagnostic products, announced that the Company and its CLIA laboratory partner have submitted an application to the American Medical Association (AMA) CPT Editorial Panel requesting the assignment of a Proprietary Laboratory Analysis (PLA) code for the inFoods® IBS diagnostic test. If granted, the PLA

      5/7/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Ulcer Test for Detection of H. pylori Infection

      10-minute test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerApproximately 80% of gastric cancer cases are linked to H. pylori infection; WHO classifies H. pylori as a Class 1 carcinogenThis test empowers healthcare providers with fast, accessible testing across the UAE IRVINE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, announced today that its Fortel® Ulcer Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This regulatory approval enables Biomerica to introduce its rapid point-of-care test for Heli

      4/23/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    SEC Filings

    See more
    • Biomerica Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BIOMERICA INC (0000073290) (Filer)

      4/16/25 9:00:09 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Biomerica Inc.

      10-Q - BIOMERICA INC (0000073290) (Filer)

      4/14/25 4:15:33 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Biomerica Inc.

      10-Q - BIOMERICA INC (0000073290) (Filer)

      1/14/25 5:06:05 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care